345 related articles for article (PubMed ID: 31379812)
1. Johnny on the Spot-Chronic Inflammation Is Driven by HMGB1.
Gorgulho CM; Romagnoli GG; Bharthi R; Lotze MT
Front Immunol; 2019; 10():1561. PubMed ID: 31379812
[TBL] [Abstract][Full Text] [Related]
2. The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases.
Wang M; Gauthier A; Daley L; Dial K; Wu J; Woo J; Lin M; Ashby C; Mantell LL
Antioxid Redox Signal; 2019 Nov; 31(13):954-993. PubMed ID: 31184204
[No Abstract] [Full Text] [Related]
3. HMGB1 Signaling-Mediated Tumor Immunity in Cancer Progress.
Wen J; Zhang X
Front Biosci (Landmark Ed); 2023 Oct; 28(10):260. PubMed ID: 37919057
[TBL] [Abstract][Full Text] [Related]
4. Sequestering of damage-associated molecular patterns (DAMPs): a possible mechanism affecting the immune-stimulating properties of aluminium adjuvants.
Svensson A; Sandberg T; Siesjö P; Eriksson H
Immunol Res; 2017 Dec; 65(6):1164-1175. PubMed ID: 29181774
[TBL] [Abstract][Full Text] [Related]
5. Macrophage-derived HMGB1 is dispensable for tissue fibrogenesis.
Personnaz J; Piccolo E; Branchereau M; Filliol A; Paccoud R; Moreau E; Calise D; Riant E; Gourdy P; Heymes C; Schwabe RF; Dray C; Valet P; Pradère JP
FASEB Bioadv; 2019 Apr; 1(4):227-245. PubMed ID: 32123829
[TBL] [Abstract][Full Text] [Related]
6. HMGB1: a double-edged sword and therapeutic target in the female reproductive system.
Ren Y; Zhu D; Han X; Zhang Q; Chen B; Zhou P; Wei Z; Zhang Z; Cao Y; Zou H
Front Immunol; 2023; 14():1238785. PubMed ID: 37691930
[TBL] [Abstract][Full Text] [Related]
7. HMGB1 in health and disease.
Kang R; Chen R; Zhang Q; Hou W; Wu S; Cao L; Huang J; Yu Y; Fan XG; Yan Z; Sun X; Wang H; Wang Q; Tsung A; Billiar TR; Zeh HJ; Lotze MT; Tang D
Mol Aspects Med; 2014 Dec; 40():1-116. PubMed ID: 25010388
[TBL] [Abstract][Full Text] [Related]
8. The multifunctional protein HMGB1: 50 years of discovery.
Tang D; Kang R; Zeh HJ; Lotze MT
Nat Rev Immunol; 2023 Dec; 23(12):824-841. PubMed ID: 37322174
[TBL] [Abstract][Full Text] [Related]
9. Metabolite-derived damage-associated molecular patterns in immunological diseases.
Kang N; Ji Z; Li Y; Gao J; Wu X; Zhang X; Duan Q; Zhu C; Xu Y; Wen L; Shi X; Liu W
FEBS J; 2024 May; 291(10):2051-2067. PubMed ID: 37432883
[TBL] [Abstract][Full Text] [Related]
10. Revealing the extracellular function of HMGB1 N-terminal region acetylation assisted by a protein semi-synthesis approach.
Wei T; Liu J; Li C; Tan Y; Wei R; Wang J; Wu H; Li Q; Liu H; Tang Y; Li X
Chem Sci; 2023 Sep; 14(37):10297-10307. PubMed ID: 37772093
[TBL] [Abstract][Full Text] [Related]
11. Targeting Inflammation Driven by HMGB1.
Yang H; Wang H; Andersson U
Front Immunol; 2020; 11():484. PubMed ID: 32265930
[TBL] [Abstract][Full Text] [Related]
12. High Mobility Group Box 1 in Human Cancer.
Rapoport BL; Steel HC; Theron AJ; Heyman L; Smit T; Ramdas Y; Anderson R
Cells; 2020 Jul; 9(7):. PubMed ID: 32664328
[TBL] [Abstract][Full Text] [Related]
13. Roles of HMGB1 in regulating myeloid-derived suppressor cells in the tumor microenvironment.
Jin S; Yang Z; Hao X; Tang W; Ma W; Zong H
Biomark Res; 2020; 8():21. PubMed ID: 32551121
[TBL] [Abstract][Full Text] [Related]
14. High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies.
Yuan S; Liu Z; Xu Z; Liu J; Zhang J
J Hematol Oncol; 2020 Jul; 13(1):91. PubMed ID: 32660524
[TBL] [Abstract][Full Text] [Related]
15. Myeloid immunosuppression and immune checkpoints in the tumor microenvironment.
Nakamura K; Smyth MJ
Cell Mol Immunol; 2020 Jan; 17(1):1-12. PubMed ID: 31611651
[TBL] [Abstract][Full Text] [Related]
16. Interactions of high mobility group box protein 1 (HMGB1) with nucleic acids: Implications in DNA repair and immune responses.
Mandke P; Vasquez KM
DNA Repair (Amst); 2019 Nov; 83():102701. PubMed ID: 31563843
[TBL] [Abstract][Full Text] [Related]
17. HMGB1: An overview of its roles in the pathogenesis of liver disease.
Ni YA; Chen H; Nie H; Zheng B; Gong Q
J Leukoc Biol; 2021 Nov; 110(5):987-998. PubMed ID: 33784425
[TBL] [Abstract][Full Text] [Related]
18. Exploring the therapeutic promise of targeting HMGB1 in rheumatoid arthritis.
Kaur I; Behl T; Bungau S; Kumar A; Mehta V; Setia D; Uddin MS; Zengin G; Aleya L; Arora S
Life Sci; 2020 Oct; 258():118164. PubMed ID: 32739467
[TBL] [Abstract][Full Text] [Related]
19. Survival of the fittest: how myeloid-derived suppressor cells survive in the inhospitable tumor microenvironment.
Ostrand-Rosenberg S; Beury DW; Parker KH; Horn LA
Cancer Immunol Immunother; 2020 Feb; 69(2):215-221. PubMed ID: 31501954
[TBL] [Abstract][Full Text] [Related]
20. Effect of dexmedetomidine on postoperative systemic inflammation and recovery in patients undergoing digest tract cancer surgery: A meta-analysis of randomized controlled trials.
Xu W; Zheng Y; Suo Z; Fei K; Wang Y; Liu C; Li S; Zhang M; Zhang Y; Zheng Z; Ni C; Zheng H
Front Oncol; 2022; 12():970557. PubMed ID: 36185178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
